0
Original Research: ASTHMA |

Improvements in Distal Lung Function Correlate With Asthma Symptoms After Treatment With Oral Montelukast*

Monica Kraft, MD, FCCP; Charles B. Cairns, MD; Misoo C. Ellison, PhD; Juno Pak, BS; Charles Irvin, PhD; Sally Wenzel, MD, FCCP
Author and Funding Information

*From the Departments of Medicine (Dr. Kraft) and Surgery (Dr. Cairns), Duke University Medical Center, Durham, NC; the Department of Medicine (Drs. Ellison and Wenzel, and Mr. Pak), National Jewish Medical and Research Center, Denver, CO; and the Department of Medicine (Dr. Irvin), University of Vermont Medical Center, Burlington, VT.

Correspondence to: Monica Kraft, MD, FCCP, Associate Professor of Medicine, Duke University Medical Center, MSBR M201D, Durham, NC 27710; e-mail: Monica.Kraft@duke.edu



Chest. 2006;130(6):1726-1732. doi:10.1378/chest.130.6.1726
Text Size: A A A
Published online

Study objectives: The distal airways are likely to contribute to asthma pathobiology and symptoms but have rarely been specifically evaluated in relation to systemic oral therapy. We hypothesized that treatment with montelukast, an oral cysteinyl-leukotriene receptor antagonist, would improve both proximal and distal lung physiology in patients with mild asthma.

Design: Randomized, double-blind, crossover design.

Setting: Academic referral center.

Patients: Subjects with mild asthma limited to using short-acting inhaled β2-agonists.

Interventions: Nineteen subjects with mild asthma underwent a baseline assessment of lung function, lung mechanics, and symptoms, followed by randomization to therapy with montelukast, 10 mg taken in the evening, or placebo in a crossover, double-blind fashion. Each treatment phase lasted 4 weeks, with a 2-week washout period. A repeat evaluation was performed during the last week of each treatment phase.

Measurements and results: Montelukast resulted in improvement in (mean ± SD) proximal and distal lung function parameters (change in FEV1: montelukast, 0.16 ± 0.06 L; placebo, −0.05 ± 0.05 L; p = 0.008); change in specific conductance: montelukast, 7.2 ± 2.9% predicted; placebo, −17 ± 8% predicted; p = 0.007; change in % predicted residual volume [RV]: montelukast, 18.4 ± 8.3% predicted; placebo, 3.0 ± 2.9% predicted; p = 0.05). Improvement in symptoms (ie, wheeze and chest tightness) correlated with improvements in RV while receiving montelukast, but not while receiving placebo (Pearson coefficients: 0.55 and 0.66, respectively; p < 0.008 and 0.04, respectively).

Conclusions: The systemically acting oral agent montelukast improves proximal and distal lung physiology. Improvements in distal lung function correlate with improvements in asthma symptoms.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
Guidelines
Long-term management of asthma.
Finnish Medical Society Duodecim | 1/11/2008
Allergic Rhinitis and its Impact on Asthma (ARIA) 2010 revision.
Allergic Rhinitis and its Impact on Asthma Workshop Group | 1/11/2008
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543